Nuvation Bio Inc
NUVB8.965USD
+0.025+0.28%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
3.07BMarket Cap
LossP/E TTM
More Details of Nuvation Bio Inc Company
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Nuvation Bio Inc Info
Ticker SymbolNUVB
Company nameNuvation Bio Inc
IPO dateJul 01, 2020
CEOHung (David T)
Number of employees220
Security typeOrdinary Share
Fiscal year-endJul 01
Address1500 Broadway
CityNEW YORK
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code10036
Phone13322086102
Websitehttps://www.nuvationbio.com/
Ticker SymbolNUVB
IPO dateJul 01, 2020
CEOHung (David T)
Company Executives of Nuvation Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
7.30K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hung (David T)
17.63%
Fidelity Management & Research Company LLC
14.64%
Decheng Capital LLC
7.59%
BlackRock Institutional Trust Company, N.A.
5.84%
The Vanguard Group, Inc.
4.50%
Other
49.78%
Shareholders
Shareholders
Proportion
Hung (David T)
17.63%
Fidelity Management & Research Company LLC
14.64%
Decheng Capital LLC
7.59%
BlackRock Institutional Trust Company, N.A.
5.84%
The Vanguard Group, Inc.
4.50%
Other
49.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.19%
Individual Investor
19.21%
Hedge Fund
11.09%
Venture Capital
10.58%
Investment Advisor/Hedge Fund
10.37%
Research Firm
1.68%
Private Equity
0.42%
Bank and Trust
0.23%
Pension Fund
0.20%
Other
15.03%
Institutional Shareholding
Updated: an hour ago
Updated: an hour ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
368
224.86M
65.78%
-37.90M
2025Q3
355
228.75M
66.72%
-24.74M
2025Q2
346
279.19M
82.03%
-27.71M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
2023Q3
285
196.95M
90.37%
-25.21M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hung (David T)
60.28M
17.61%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.47M
14.75%
+440.09K
+0.88%
Jun 30, 2025
Decheng Capital LLC
25.95M
7.58%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
20.99M
6.13%
+5.12M
+32.27%
Jun 30, 2025
The Vanguard Group, Inc.
15.84M
4.63%
+505.23K
+3.29%
Jun 30, 2025
Laurion Capital Management LP
10.24M
2.99%
+369.63K
+3.74%
Jun 30, 2025
Omega Fund Management, LLC
11.04M
3.23%
-2.03M
-15.53%
Jun 30, 2025
State Street Investment Management (US)
5.56M
1.62%
+702.97K
+14.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.99M
1.75%
+864.19K
+16.84%
Jun 30, 2025
Millennium Management LLC
5.38M
1.57%
+1.61M
+42.56%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
2.51%
Virtus LifeSci Biotech Clinical Trials ETF
1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.79%
Tema Oncology ETF
1.66%
ALPS Medical Breakthroughs ETF
0.74%
iShares U.S. Pharmaceuticals ETF
0.46%
iShares Micro-Cap ETF
0.25%
iShares Health Innovation Active ETF
0.24%
Avantis US Small Cap Equity ETF
0.16%
iShares Biotechnology ETF
0.11%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.51%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.79%
Tema Oncology ETF
Proportion1.66%
ALPS Medical Breakthroughs ETF
Proportion0.74%
iShares U.S. Pharmaceuticals ETF
Proportion0.46%
iShares Micro-Cap ETF
Proportion0.25%
iShares Health Innovation Active ETF
Proportion0.24%
Avantis US Small Cap Equity ETF
Proportion0.16%
iShares Biotechnology ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Nuvation Bio Inc?
The top five shareholders of Nuvation Bio Inc are:
Hung (David T) holds 60.28M shares, accounting for 17.61% of the total shares.
Fidelity Management & Research Company LLC holds 50.47M shares, accounting for 14.75% of the total shares.
Decheng Capital LLC holds 25.95M shares, accounting for 7.58% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 20.99M shares, accounting for 6.13% of the total shares.
The Vanguard Group, Inc. holds 15.84M shares, accounting for 4.63% of the total shares.
Hung (David T) holds 60.28M shares, accounting for 17.61% of the total shares.
Fidelity Management & Research Company LLC holds 50.47M shares, accounting for 14.75% of the total shares.
Decheng Capital LLC holds 25.95M shares, accounting for 7.58% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 20.99M shares, accounting for 6.13% of the total shares.
The Vanguard Group, Inc. holds 15.84M shares, accounting for 4.63% of the total shares.
What are the top three shareholder types of Nuvation Bio Inc?
The top three shareholder types of Nuvation Bio Inc are:
Hung (David T)
Fidelity Management & Research Company LLC
Decheng Capital LLC
Hung (David T)
Fidelity Management & Research Company LLC
Decheng Capital LLC
How many institutions hold shares of Nuvation Bio Inc (NUVB)?
As of 2025Q4, 368 institutions hold shares of Nuvation Bio Inc, with a combined market value of approximately 224.86M, accounting for 65.78% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.94%.
What is the biggest source of revenue for Nuvation Bio Inc?
In --, the -- business generated the highest revenue for Nuvation Bio Inc, amounting to -- and accounting for --% of total revenue.
